News Novo Nordisk staff cull swells to 1,300 Novo Nordisk has raised the number of staff it will shed this year in order to invest more in developing new drugs and supporting its most important products.
News AZ's Imfinzi set for EU return in bladder cancer AstraZeneca passes another milestone in its journey to rebuild Imfinzi's presence in bladder cancer, a key growth driver for the drug.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face